FolioLanternBeta
ADRXADARx Pharmaceuticals, Inc. · Insider ownership research

ADARx Pharmaceuticals, Inc. insiders: what they own and what they did with it

None of it through sales. No officer or director reported an open-market sale in this period.

Updated Oct 13, 2026 from SEC filings · covers Oct 14, 2025 to Oct 13, 2026
1
buyer among officers and directors (3 trades), past 12 months
0 of 9
officers and directors sold shares, past 12 months
Latest filing: Filed Sep 30 for a transaction on Sep 28. Carl Gordon reported a change in holdings. Filing
SEC ownership filings: 24 filed in the 12 months to Oct 13, 2026; 24 on record since Sep 24, 2026 · See the evidence

What stands out

Simeon George bought 1.60M shares for $27.2M, first on Sep 28, 2026. These are the first purchases by current officers or directors in the filings on record.Purchase, Sep 28, 2026

No officer or director sold shares in this period. 9 are left out

i
Left out: Zhen Li, Rui Zhu, Carl Gordon, Ryan Fisk, Alan MacLeod, Robert Ackles, Mary Tagliaferri, Ying Huang and Simeon George (share of stake is being verified).
Disclosed company stock is not an insider's whole wealth.

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026
Sep 28, 2026Simeon George bought 1.60M shares ($27.2M).
WhoSharesPrice% of total stakeTotal stake afterTrade dateFiled
Simeon George
Director
1,600,000$17.00n/an/aSep 28, 2026Sep 29, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

LAV Biosciences Fund V, L.P., ORBIMED ADVISORS LLC and SR ONE CAPITAL MANAGEMENT, LLC and 2 more reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the ADARx Pharmaceuticals, Inc. CEO selling stock?

No. Zhen Li reported no open-market sales in the past 12 months.

Are any ADARx Pharmaceuticals, Inc. insiders buying?

Yes. 1 officer or director reported 3 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold0 officers and directors: amount, % of holdings, trading plan
Who soldAmount% of holdingsTrading plan

Board members representing outside shareholders, reported separately: Carl Gordon, Erez Chimovits. Details

Outside holder, reported separately: LAV Biosciences Fund V, L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: ORBIMED ADVISORS LLC (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: SR ONE CAPITAL MANAGEMENT, LLC (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 9 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

InsiderHeld Oct 13, 2025SoldHeld Oct 13, 2026Still held
Zhen Li
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Zhen Li are complete.
President and CEO, Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Zhen Li

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Zhen Li are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
1,171,325$0.24Aug 19, 2030$19.6M
327,378$0.24Dec 6, 2030$5.5M
320,500$0.24Mar 18, 2031$5.4M
845,726$0.56May 20, 2031$13.9M
710,541$2.29Jul 29, 2031$10.5M
436,715$2.29Feb 22, 2032$6.4M
436,715$3.26Feb 25, 2033$6.0M
773,085$5.84Jan 16, 2034$8.6M
426,730$7.05Feb 11, 2035$4.2M
443,799$6.31Jan 27, 2036$4.7M
1,024,152$17.00Sep 23, 2036$0
17,069$0.24Aug 19, 2030$286K
12,801$0.24Mar 18, 2031$215K
8,534$2.29Feb 22, 2032$126K
6,827$3.26Feb 25, 2033$94K
5,120$5.84Jan 16, 2034$57K
5,120$7.05Feb 11, 2035$51K
12,801$6.31Jan 27, 2036$137K

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Sep 28, 2026), not a market close.

Rui Zhu
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Rui Zhu are complete.
Chief Technology Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Rui Zhu

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Rui Zhu are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
501,996$0.24Aug 19, 2030$8.4M
140,305$0.24Dec 6, 2030$2.4M
34,138$0.24Mar 18, 2031$572K
362,453$0.56May 20, 2031$6.0M
34,138$2.29Feb 22, 2032$502K
42,673$3.26Feb 25, 2033$586K
51,207$5.84Jan 16, 2034$571K
42,673$7.05Feb 11, 2035$425K
68,276$6.31Jan 27, 2036$730K
512,076$17.00Sep 23, 2036$0

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Sep 28, 2026), not a market close.

Carl Gordon
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Carl Gordon are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Carl Gordon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Carl Gordon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
Ryan Fisk
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Ryan Fisk are complete.
CFO and CBO
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Ryan Fisk

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ryan Fisk are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
865,864$6.31Mar 23, 2036$9.3M
170,692$17.00Sep 23, 2036$0

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Sep 28, 2026), not a market close.

Alan MacLeod
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Alan MacLeod are complete.
Chief Scientific Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Alan MacLeod

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alan MacLeod are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
513,401$3.26Feb 25, 2033$7.1M
42,673$5.84Jan 16, 2034$476K
42,673$7.05Feb 11, 2035$425K
68,276$6.31Jan 27, 2036$730K
170,692$17.00Sep 23, 2036$0

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Sep 28, 2026), not a market close.

Robert Ackles
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Robert Ackles are complete.
Chief People Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Robert Ackles

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Ackles are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
335,633$8.69Aug 16, 2036$2.8M
85,346$17.00Sep 23, 2036$0

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Sep 28, 2026), not a market close.

Mary Tagliaferri
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Mary Tagliaferri are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Mary Tagliaferri

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mary Tagliaferri are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
178,528$6.25Nov 21, 2035$1.9M
178,528$8.69Jul 19, 2036$1.5M

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Sep 28, 2026), not a market close.

Ying Huang
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Ying Huang are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Ying Huang

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ying Huang are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
267,792$8.69Jul 19, 2036$2.2M

Estimate: options held × ($17.00 − strike price), using the most recent insider trade price on Form 4 (Sep 28, 2026), not a market close.

Simeon George
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Simeon George are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Simeon George

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Simeon George are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Holdings and share of stake for ADARx Pharmaceuticals, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

Board members representing outside shareholders (2)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board memberHeld Oct 13, 2025SoldHeld Oct 13, 2026Still held
Carl Gordon
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Carl Gordon are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Carl Gordon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Carl Gordon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
Erez Chimovits
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Erez Chimovits are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Erez Chimovits

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Erez Chimovits are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)
Known gaps and uncertainty9 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for ADARx Pharmaceuticals, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology24 filings on record, 24 filed in the 12-month period, and how we read them

All 24 Forms 3, 4 and 5 on record for ADARx Pharmaceuticals, Inc. (SEC CIK 1802369), filed from Sep 24, 2026 to Sep 30, 2026; 24 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.